98%
921
2 minutes
20
The WHO has given a permissive recommendation for an off-label one-dose human papillomavirus (HPV) vaccine schedule to prevent cervical cancer, based on evidence of comparable protection to two or three doses of vaccine. While neutralizing antibodies are thought to be the primary mechanism of protection, the persistence of immunity and whether other antibody-mediated mechanisms of protection are involved is unclear. Using systems serology, we investigated HPV antibody responses in serum from Fijian girls who were unvaccinated or received one, two or three doses of quadrivalent HPV vaccine six years earlier. We also evaluated their HPV antibody responses 28 days following a dose of bivalent HPV vaccine. After six years, one dose induced lower antibody concentrations but similar antibody profiles and phagocytic function as two or three doses. Following bivalent vaccine, antibody concentrations, particularly IgG1/IgG3, antibody profiles and phagocytic function were similar between previously vaccinated girls, indicating immune memory after one dose. Cross-reactive antibody responses against non-vaccine genotypes (HPV31/33/45/52/58) were lower following one dose than two or three doses. These findings provide novel insights into serological immunity and recall responses following one-dose HPV vaccination.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876628 | PMC |
http://dx.doi.org/10.1038/s41467-025-57443-z | DOI Listing |
Sex Transm Dis
September 2025
University of Illinois at Chicago School of Public Health, 1603 W. Taylor St., Chicago, IL, 60612.
Background: Human papillomavirus (HPV) is a leading cause of six cancers. Despite effective vaccines, HPV vaccination rates remain suboptimal, standing at 26% of females and 9% of males, nationally in 2018. This study assessed factors associated with HPV vaccination uptake among patients at Chicago Department of Public Health (CDPH) STI Specialty Clinics.
View Article and Find Full Text PDFInt J Cancer
September 2025
Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, Quebec, Canada.
In Canada, the incidence of human papillomavirus (HPV)-related head and neck cancer (HNC) is increasing. The role of multiple oral HPV infections in HNC etiology remains unclear, and evidence of HPV vaccination's effectiveness in reducing HNC incidence is limited. We investigated oral HPV co-infection patterns, estimated the association between multiple oral HPV infections and HNC risk, and the effect of eliminating vaccine-targeted HPV genotypes on HNC incidence.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2025
Department of Epidemiology, Ministry of Education Key Laboratory of Public Health Safety, School of Public Health, Fudan University, Shanghai, China.
Human papillomavirus (HPV) causes multiple diseases in both sexes. This study evaluates the cost-effectiveness and epidemiological impact - defined as reductions in HPV-related disease cases - of a gender-neutral vaccination (GNV) strategy in China's economically developed metropolises: Beijing, Shanghai, and Guangzhou. A discrete-time Markov model simulated no vaccination, female-only vaccination (FOV), and GNV strategies among 12-year-olds.
View Article and Find Full Text PDFAfr J Prim Health Care Fam Med
August 2025
Department of Preventative Health Sciences, Faculty of Health, Natural Resources and Applied Sciences, Namibia University of Science and Technology (NUST), Windhoek.
Background: Cervical cancer remains a pressing public health concern in Namibia, with significant barriers to prevention, particularly in rural areas.
Aim: This study explored health system's challenges and their impact on cervical cancer prevention efforts.
Setting: This study was conducted in the Ohangwena and Kavango West regions of Namibia.
J Infect Dev Ctries
August 2025
Scientific Research Centre for Public Health, University of Vlore "Ismail Qemali", Vlore, Albania.
Introduction: Despite the HPV vaccine's efficacy in cervical cancer prevention, cervical cancer ranks second in prevalence among women, following breast cancer. Various factors negatively impact HPV vaccination uptake, with parents' knowledge and attitudes being particularly crucial in this regard.
Methodology: A cross-sectional study was conducted between February and May 2023, targeting parents in northern Albania.